Skip to Content

Boostrix GlaxoSmithKline Biologicals - Treatment for Prevention of Diphtheria, Tetanus & Pertussis in Adolescents

Boostrix is indicated as a single dose active booster immunization against tetanus, diphtheria, and pertussis in individuals 10 through 18 years of age, thereby adding a pertussis component to the routine tetanus/diphtheria booster currently administered to teens.

Posted: May 2005

Related Articles:

Boostrix (tetanus, diphtheria, acellular pertussis vaccine (Tdap)) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.